Reductions in glycemic variability (GV) may be associated with decrease in cardiovascular complications. This analysis assessed GV in people with type 2 diabetes receiving dulaglutide (DU) 1.5 mg once weekly or basal insulin glargine (IGlar) in two clinical trials. AWARD (AW) 2 participants on metformin and glimepiride randomized to DU (N=173) or IGlar (N=161). AW9 participants randomized to DU (N=127) or placebo (N=120), both added to IGlar with/without metformin. GV measured at baseline and study endpoint (AW2: week 26; AW9: week 28). Studies analyzed separately for within-day and between-day GV from self-monitored blood glucose (SMPG), and between-day GV from fasting self-measured plasma glucose (FSMPG), by standard deviation (SD). AW2 DU and IGlar arms were 54% and 51% male at baseline; mean (SD) HbA1c of 8.2 (1.0) and 8.1 (0.9) %; fasting plasma glucose (FPG) 162.0 (46.7) and 161.1 (47.1) mg/dL. DU treatment yielded significantly greater reductions in within-day SMPG GV (Figure) than IGlar. AW9 DU+IGlar and Placebo+IGlar arms included 58% and 58% male participants; mean (SD) HbA1c was 8.4 (0.8) and 8.2 (0.8) %; FPG 154.5 (46.5) and 155.0 (46.7) mg/dL. DU+IGlar showed significantly greater reductions in within-day and between-day GV from SMPG (Figure), and between-day FSMPG GV than placebo+IGlar. DU treatment showed a greater reduction in within-day SMPG GV versus IGlar. DU+IGlar reduces SMPG GV and FSMPG GV more than placebo+IGlar.
E. Jodar: Other Relationship; Self; Elli Lilly & Co, Novo Nordisk, MSD, Lilly, Janssen, Pfizer, AstraZeneca, Sanofi, UCB, Amgen, FAES, Shire, Mundipharma, Novartis. I. Romera: Employee; Self; Eli Lilly and Company. Q. Wang: Employee; Self; Eli Lilly and Company. E. Caveda: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company. L. Garcia: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company.
Eli Lilly and Company
